Tianyan Pharmaceutical and Tanabe Research Laboratory have reached a cooperation to help develop new antibody conjugate drugs

On June 10, Tianbe Research Laboratories U.S.A., Inc., TRL, a subsidiary of Mitsubishi Pharmaceuticals, announced a strategic partnership with TaatseiTRL will develop a new generation of antibody conjugate drugs (ADCs) for solid tumor targets using safEbody ® (Safe Antibody Platform), a proprietary antibody masking technology developed by Tianyin PharmaceuticalsThe specific financial terms and target information of this partnership were not disclosedTianxing Pharmaceuticals is a clinical pharmaceutical company, committed to creating a "dynamic precision antibody bank" with independent intellectual property rights, and a new generation of antibody precision masking technology SAFEbody ® and its unique original antibody product lineThe field of tumor immunology and targeted treatment is deeply laid out, driven by target and antibody technology innovation, based on sufficient translational medical data, and striveto achieve a breakthrough in clinical efficacy and safety of the productIt is reported that the safety antibody platform developed by Tianyin Pharmaceuticals aims to improve the safety of antibody drugs through precision antibody masking technologySafety antibodies are specifically activated in disease tissue, reducing systemic toxicity while enhancing the targetspecificness of the antibody, which makes antibody conjugated drug delivery cytotoxins more accurate and effective, thereby improving its therapeutic indexTRL, based in San Diego, USA, is an independent subsidiary of Tatseiki Mitsubishi Pharmaceuticals, incand specializes in the development of new therapeutic drugsTRL is currently working on antibody and antibody-related products for the treatment of other diseases such as tumors"We are very much looking forward to this collaboration, combining the SAFEbody ® technology and TRL's ADC technology to develop innovative drugs for specific tumor targets"The cytotoxic side effects at the best effective dose limit the use of traditional ADC technology on most solid tumor targets, and Tianshi's precision protein engineering technology can maintain its efficacy while building high-masking safety antibodies, using our POWEBody ®, combining SAFEbody ® with ADC technology to break through this limitation and develop safe and effective drugs for more targets." "